Company: CORT
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001628280-25-037005
Chunk: 4

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 of restricted stock(262)— — (19,221)— — (19,221)Repurchase of common stock in connection with Stock Repurchase Program(1,482)— — (103,018)— — (103,018)Stock-based compensation— — 19,427 — — — 19,427 Vesting of RSAs in connection with ESPP— — 3,449 — — — 3,449 Other comprehensive gain, net of tax— — — — 1,599 — 1,599 Net income— — — — — 35,149 35,149 Balance at June 30, 2025105,288 $138 $900,864 $(866,931)$2,291 $599,431 $635,793 

The accompanying notes are an integral part of these condensed consolidated financial statements.

8

Common StockAdditionalPaid-inCapitalTreasury StockAccumulatedOtherComprehensiveIncome (Loss)Retained EarningsTotalStockholders’EquitySharesAmountBalance at December 31, 2023103,405 $133 $738,515 $(635,078)$609 $402,526 $506,705 Issuance of common stock under incentive award plan786 — 3,485 — — — 3,485 Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock(143)— 2,032 (5,586)— — (3,554)Repurchase of common stock in connection with Stock Repurchase Program(20)— — (476)— — (476)Excise tax related to net share repurchases— — — 81 — — 81 Stock-based compensation— — 12,929 — — — 12,929 Vesting of RSAs in connection with ESPP— $— $1,283 $— $— $— $1,283 Other comprehensive loss, net of tax— $— $— $— $(351)$— $(351)Net income— $— $— $— $— $27,762 $27,762 Balance at March 31,